Ipsen bets up to $363M on another shot at a debilitating condition related to Parkinson's disease

Ipsen is in a deal-making mood. On Thursday, the company put down $28 million upfront and another $335 million in biobucks for the rights to IRLAB’s mid-stage candidate for levodopa-induced dyskinesia (LID) — a condition related to Parkinson’s disease that tripped up the French biotech about a decade ago.